US and UK Announce Duty-Free Pact on Drugs.

The United Kingdom and the United States have announced a significant trade agreement that will keep no import taxes on UK drug exports entering the US market.

The Terms of the Accord

In exchange for the tariff guarantee, the UK has pledged to boost funding on medicines through the NHS. This move secures that tariffs on these vital goods will be held at zero for a period of the next three years.

This agreement follows previous statements to hike tariffs on branded pharmaceutical imports, with potential rates discussed as high as one hundred percent.

"This arrangement with the United Kingdom bolsters the worldwide climate for innovative medicines and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement declared.

Trade Significance

Drugs constitute one of the the United Kingdom's biggest goods shipped to the America, which is by far the largest destination for leading UK drugmakers.

Export figures reveal that in the 12 months prior to the third quarter, the UK exported drugs valued at £11.1bn to the US. This value made up 17.4% of total UK exports in that period.

"This agreement protects employment, stimulates funding and sets the stage for the UK to emerge as a global hub for life sciences," a government official commented.

Specific NHS Changes

The pact includes several key changes from the UK:

• Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by 25%.
• Higher Drug Budget: There is a goal to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
• Rebate Cap: The sum manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates topped 20%.

Industry Background

The deal follows a long-running tension between the drug companies and the British authorities over drug pricing and NHS adoption.

The disagreement were exacerbated by claims that US patients were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.

Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been directed toward American operations.

The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.